http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 28 Aug 2026 09:22:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CYTOKINETICS+INC++++++++++For%3A+Aug+28/26993767.html si-local-file:///var/storage/secattach/20260828/26993767.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CYTOKINETICS+INC++++++++++For%3A+Aug+28/26993767.html Fri, 28 Aug 2026 09:22:00 -0400 CYTK O.00016952 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CYTOKINETICS+INC++++++++++For%3A+Aug+28/26993767.html si-local-file:///var/storage/secattach/20260828/26993767.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CYTOKINETICS+INC++++++++++For%3A+Aug+28/26993767.html Fri, 28 Aug 2026 09:22:00 -0400 CYTK O.00016952 http://www.streetinsider.com/Corporate+News/Cytokinetics+aficamten+meets+dual+endpoints+in+non-obstructive+HCM+trial/26992225.html <p>Cytokinetics, Incorporated (Nasdaq: CYTK) announced that its Phase 3 ACACIA-HCM clinical trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM) met both dual primary endpoints, according to results presented at the European Society of Cardiology Congress 2026 in Munich, Germany, and simultaneously published in <em>The New England Journal of Medicine</em>.</p><p>The trial of 517 participants showed statistically significant improvements from baseline to Week 36 compared to placebo in both the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) and maximal exercise performance (pVO2). The KCCQ-CSS improvement for aficamten versus placebo showed a least square mean difference of 3.0 points http://www.streetinsider.com/Corporate+News/Cytokinetics+aficamten+meets+dual+endpoints+in+non-obstructive+HCM+trial/26992225.html Fri, 28 Aug 2026 05:51:41 -0400 CYTK http://www.streetinsider.com/FDA/Cytokinetics+aficamten+meets+dual+endpoints+in+non-obstructive+HCM+trial/26992225.html <p>Cytokinetics, Incorporated (Nasdaq: CYTK) announced that its Phase 3 ACACIA-HCM clinical trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM) met both dual primary endpoints, according to results presented at the European Society of Cardiology Congress 2026 in Munich, Germany, and simultaneously published in <em>The New England Journal of Medicine</em>.</p><p>The trial of 517 participants showed statistically significant improvements from baseline to Week 36 compared to placebo in both the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) and maximal exercise performance (pVO2). The KCCQ-CSS improvement for aficamten versus placebo showed a least square mean difference of 3.0 points http://www.streetinsider.com/FDA/Cytokinetics+aficamten+meets+dual+endpoints+in+non-obstructive+HCM+trial/26992225.html Fri, 28 Aug 2026 05:51:41 -0400 CYTK http://www.streetinsider.com/Press+Releases/Cytokinetics+Announces+Positive+Results+from+ACACIA-HCM+Presented+in+Hot+Line+Session+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026+and+Published+in+The+New+England+Journal+of+Medicine/26992211.html <p align="center"><em>ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCM</em></p> <p align="center"><em>Supplemental New Drug Application to be Submitted to FDA in Fourth Quarter</em></p> <p align="center"><em>Company to Host Investor Event and Webcast Today at 2:00 PM Central European Summer Time (8:00 AM Eastern Time)</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the primary results from ACACIA-HCM (<strong>A</strong>ssessment <strong>C</strong>omparing <strong><em>A</em></strong><em>ficamten</em> to Placebo on <strong>C</strong>ardiac Endpoints <strong>I</strong>n <strong>A</strong>dults with Non-Obstructive <strong>HCM</strong>), the pivotal Phase http://www.streetinsider.com/Press+Releases/Cytokinetics+Announces+Positive+Results+from+ACACIA-HCM+Presented+in+Hot+Line+Session+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026+and+Published+in+The+New+England+Journal+of+Medicine/26992211.html Fri, 28 Aug 2026 05:45:00 -0400 A.06822034 A.09649487 A.33151435 CYTK O.00016952 O.00048429 O.02147044 O.20026344 http://www.streetinsider.com/Press+Releases/Cytokinetics+Announces+Positive+Results+from+ACACIA-HCM+Presented+in+Hot+Line+Session+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026+and+Published+in+The+New+England+Journal+of+Medicine/26992211.html <p align="center"><em>ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCM</em></p> <p align="center"><em>Supplemental New Drug Application to be Submitted to FDA in Fourth Quarter</em></p> <p align="center"><em>Company to Host Investor Event and Webcast Today at 2:00 PM Central European Summer Time (8:00 AM Eastern Time)</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the primary results from ACACIA-HCM (<strong>A</strong>ssessment <strong>C</strong>omparing <strong><em>A</em></strong><em>ficamten</em> to Placebo on <strong>C</strong>ardiac Endpoints <strong>I</strong>n <strong>A</strong>dults with Non-Obstructive <strong>HCM</strong>), the pivotal Phase http://www.streetinsider.com/Press+Releases/Cytokinetics+Announces+Positive+Results+from+ACACIA-HCM+Presented+in+Hot+Line+Session+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026+and+Published+in+The+New+England+Journal+of+Medicine/26992211.html Fri, 28 Aug 2026 05:45:00 -0400 A.06822034 A.09649487 A.33151435 CYTK O.00016952 O.00048429 O.02147044 O.20026344 http://www.streetinsider.com/Press+Releases/Cytokinetics+Announces+Positive+Results+from+ACACIA-HCM+Presented+in+Hot+Line+Session+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026+and+Published+in+The+New+England+Journal+of+Medicine/26992211.html <p align="center"><em>ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCM</em></p> <p align="center"><em>Supplemental New Drug Application to be Submitted to FDA in Fourth Quarter</em></p> <p align="center"><em>Company to Host Investor Event and Webcast Today at 2:00 PM Central European Summer Time (8:00 AM Eastern Time)</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the primary results from ACACIA-HCM (<strong>A</strong>ssessment <strong>C</strong>omparing <strong><em>A</em></strong><em>ficamten</em> to Placebo on <strong>C</strong>ardiac Endpoints <strong>I</strong>n <strong>A</strong>dults with Non-Obstructive <strong>HCM</strong>), the pivotal Phase http://www.streetinsider.com/Press+Releases/Cytokinetics+Announces+Positive+Results+from+ACACIA-HCM+Presented+in+Hot+Line+Session+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026+and+Published+in+The+New+England+Journal+of+Medicine/26992211.html Fri, 28 Aug 2026 05:45:00 -0400 A.06822034 A.09649487 A.33151435 CYTK O.00016952 O.00048429 O.02147044 O.20026344 http://www.streetinsider.com/Press+Releases/Cytokinetics+Announces+Positive+Results+from+ACACIA-HCM+Presented+in+Hot+Line+Session+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026+and+Published+in+The+New+England+Journal+of+Medicine/26992211.html <p align="center"><em>ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCM</em></p> <p align="center"><em>Supplemental New Drug Application to be Submitted to FDA in Fourth Quarter</em></p> <p align="center"><em>Company to Host Investor Event and Webcast Today at 2:00 PM Central European Summer Time (8:00 AM Eastern Time)</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the primary results from ACACIA-HCM (<strong>A</strong>ssessment <strong>C</strong>omparing <strong><em>A</em></strong><em>ficamten</em> to Placebo on <strong>C</strong>ardiac Endpoints <strong>I</strong>n <strong>A</strong>dults with Non-Obstructive <strong>HCM</strong>), the pivotal Phase http://www.streetinsider.com/Press+Releases/Cytokinetics+Announces+Positive+Results+from+ACACIA-HCM+Presented+in+Hot+Line+Session+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026+and+Published+in+The+New+England+Journal+of+Medicine/26992211.html Fri, 28 Aug 2026 05:45:00 -0400 A.06822034 A.09649487 A.33151435 CYTK O.00016952 O.00048429 O.02147044 O.20026344 http://www.streetinsider.com/Press+Releases/Cytokinetics+Announces+Positive+Results+from+ACACIA-HCM+Presented+in+Hot+Line+Session+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026+and+Published+in+The+New+England+Journal+of+Medicine/26992211.html <p align="center"><em>ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCM</em></p> <p align="center"><em>Supplemental New Drug Application to be Submitted to FDA in Fourth Quarter</em></p> <p align="center"><em>Company to Host Investor Event and Webcast Today at 2:00 PM Central European Summer Time (8:00 AM Eastern Time)</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the primary results from ACACIA-HCM (<strong>A</strong>ssessment <strong>C</strong>omparing <strong><em>A</em></strong><em>ficamten</em> to Placebo on <strong>C</strong>ardiac Endpoints <strong>I</strong>n <strong>A</strong>dults with Non-Obstructive <strong>HCM</strong>), the pivotal Phase http://www.streetinsider.com/Press+Releases/Cytokinetics+Announces+Positive+Results+from+ACACIA-HCM+Presented+in+Hot+Line+Session+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026+and+Published+in+The+New+England+Journal+of+Medicine/26992211.html Fri, 28 Aug 2026 05:45:00 -0400 A.06822034 A.09649487 A.33151435 CYTK O.00016952 O.00048429 O.02147044 O.20026344 http://www.streetinsider.com/Press+Releases/Cytokinetics+Announces+Positive+Results+from+ACACIA-HCM+Presented+in+Hot+Line+Session+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026+and+Published+in+The+New+England+Journal+of+Medicine/26992211.html <p align="center"><em>ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCM</em></p> <p align="center"><em>Supplemental New Drug Application to be Submitted to FDA in Fourth Quarter</em></p> <p align="center"><em>Company to Host Investor Event and Webcast Today at 2:00 PM Central European Summer Time (8:00 AM Eastern Time)</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the primary results from ACACIA-HCM (<strong>A</strong>ssessment <strong>C</strong>omparing <strong><em>A</em></strong><em>ficamten</em> to Placebo on <strong>C</strong>ardiac Endpoints <strong>I</strong>n <strong>A</strong>dults with Non-Obstructive <strong>HCM</strong>), the pivotal Phase http://www.streetinsider.com/Press+Releases/Cytokinetics+Announces+Positive+Results+from+ACACIA-HCM+Presented+in+Hot+Line+Session+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026+and+Published+in+The+New+England+Journal+of+Medicine/26992211.html Fri, 28 Aug 2026 05:45:00 -0400 A.06822034 A.09649487 A.33151435 CYTK O.00016952 O.00048429 O.02147044 O.20026344 http://www.streetinsider.com/Press+Releases/Cytokinetics+Announces+Positive+Results+from+ACACIA-HCM+Presented+in+Hot+Line+Session+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026+and+Published+in+The+New+England+Journal+of+Medicine/26992211.html <p align="center"><em>ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCM</em></p> <p align="center"><em>Supplemental New Drug Application to be Submitted to FDA in Fourth Quarter</em></p> <p align="center"><em>Company to Host Investor Event and Webcast Today at 2:00 PM Central European Summer Time (8:00 AM Eastern Time)</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the primary results from ACACIA-HCM (<strong>A</strong>ssessment <strong>C</strong>omparing <strong><em>A</em></strong><em>ficamten</em> to Placebo on <strong>C</strong>ardiac Endpoints <strong>I</strong>n <strong>A</strong>dults with Non-Obstructive <strong>HCM</strong>), the pivotal Phase http://www.streetinsider.com/Press+Releases/Cytokinetics+Announces+Positive+Results+from+ACACIA-HCM+Presented+in+Hot+Line+Session+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026+and+Published+in+The+New+England+Journal+of+Medicine/26992211.html Fri, 28 Aug 2026 05:45:00 -0400 A.06822034 A.09649487 A.33151435 CYTK O.00016952 O.00048429 O.02147044 O.20026344 http://www.streetinsider.com/Press+Releases/Cytokinetics+Announces+Positive+Results+from+ACACIA-HCM+Presented+in+Hot+Line+Session+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026+and+Published+in+The+New+England+Journal+of+Medicine/26992211.html <p align="center"><em>ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCM</em></p> <p align="center"><em>Supplemental New Drug Application to be Submitted to FDA in Fourth Quarter</em></p> <p align="center"><em>Company to Host Investor Event and Webcast Today at 2:00 PM Central European Summer Time (8:00 AM Eastern Time)</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the primary results from ACACIA-HCM (<strong>A</strong>ssessment <strong>C</strong>omparing <strong><em>A</em></strong><em>ficamten</em> to Placebo on <strong>C</strong>ardiac Endpoints <strong>I</strong>n <strong>A</strong>dults with Non-Obstructive <strong>HCM</strong>), the pivotal Phase http://www.streetinsider.com/Press+Releases/Cytokinetics+Announces+Positive+Results+from+ACACIA-HCM+Presented+in+Hot+Line+Session+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026+and+Published+in+The+New+England+Journal+of+Medicine/26992211.html Fri, 28 Aug 2026 05:45:00 -0400 A.06822034 A.09649487 A.33151435 CYTK O.00016952 O.00048429 O.02147044 O.20026344 http://www.streetinsider.com/Globe+Newswire/Cytokinetics+Announces+Positive+Results+from+ACACIA-HCM+Presented+in+Hot+Line+Session+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026+and+Published+in+The+New+England+Journal+of+Medicine/26992211.html <p align="center"><em>ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCM</em></p> <p align="center"><em>Supplemental New Drug Application to be Submitted to FDA in Fourth Quarter</em></p> <p align="center"><em>Company to Host Investor Event and Webcast Today at 2:00 PM Central European Summer Time (8:00 AM Eastern Time)</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the primary results from ACACIA-HCM (<strong>A</strong>ssessment <strong>C</strong>omparing <strong><em>A</em></strong><em>ficamten</em> to Placebo on <strong>C</strong>ardiac Endpoints <strong>I</strong>n <strong>A</strong>dults with Non-Obstructive <strong>HCM</strong>), the pivotal Phase http://www.streetinsider.com/Globe+Newswire/Cytokinetics+Announces+Positive+Results+from+ACACIA-HCM+Presented+in+Hot+Line+Session+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026+and+Published+in+The+New+England+Journal+of+Medicine/26992211.html Fri, 28 Aug 2026 05:45:00 -0400 A.06822034 A.09649487 A.33151435 CYTK O.00016952 O.00048429 O.02147044 O.20026344 http://www.streetinsider.com/Globe+Newswire/Cytokinetics+Announces+Positive+Results+from+ACACIA-HCM+Presented+in+Hot+Line+Session+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026+and+Published+in+The+New+England+Journal+of+Medicine/26992211.html <p align="center"><em>ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCM</em></p> <p align="center"><em>Supplemental New Drug Application to be Submitted to FDA in Fourth Quarter</em></p> <p align="center"><em>Company to Host Investor Event and Webcast Today at 2:00 PM Central European Summer Time (8:00 AM Eastern Time)</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the primary results from ACACIA-HCM (<strong>A</strong>ssessment <strong>C</strong>omparing <strong><em>A</em></strong><em>ficamten</em> to Placebo on <strong>C</strong>ardiac Endpoints <strong>I</strong>n <strong>A</strong>dults with Non-Obstructive <strong>HCM</strong>), the pivotal Phase http://www.streetinsider.com/Globe+Newswire/Cytokinetics+Announces+Positive+Results+from+ACACIA-HCM+Presented+in+Hot+Line+Session+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026+and+Published+in+The+New+England+Journal+of+Medicine/26992211.html Fri, 28 Aug 2026 05:45:00 -0400 A.06822034 A.09649487 A.33151435 CYTK O.00016952 O.00048429 O.02147044 O.20026344 http://www.streetinsider.com/Globe+Newswire/Cytokinetics+Announces+Positive+Results+from+ACACIA-HCM+Presented+in+Hot+Line+Session+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026+and+Published+in+The+New+England+Journal+of+Medicine/26992211.html <p align="center"><em>ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCM</em></p> <p align="center"><em>Supplemental New Drug Application to be Submitted to FDA in Fourth Quarter</em></p> <p align="center"><em>Company to Host Investor Event and Webcast Today at 2:00 PM Central European Summer Time (8:00 AM Eastern Time)</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the primary results from ACACIA-HCM (<strong>A</strong>ssessment <strong>C</strong>omparing <strong><em>A</em></strong><em>ficamten</em> to Placebo on <strong>C</strong>ardiac Endpoints <strong>I</strong>n <strong>A</strong>dults with Non-Obstructive <strong>HCM</strong>), the pivotal Phase http://www.streetinsider.com/Globe+Newswire/Cytokinetics+Announces+Positive+Results+from+ACACIA-HCM+Presented+in+Hot+Line+Session+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026+and+Published+in+The+New+England+Journal+of+Medicine/26992211.html Fri, 28 Aug 2026 05:45:00 -0400 A.06822034 A.09649487 A.33151435 CYTK O.00016952 O.00048429 O.02147044 O.20026344 http://www.streetinsider.com/Globe+Newswire/Cytokinetics+Announces+Positive+Results+from+ACACIA-HCM+Presented+in+Hot+Line+Session+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026+and+Published+in+The+New+England+Journal+of+Medicine/26992211.html <p align="center"><em>ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCM</em></p> <p align="center"><em>Supplemental New Drug Application to be Submitted to FDA in Fourth Quarter</em></p> <p align="center"><em>Company to Host Investor Event and Webcast Today at 2:00 PM Central European Summer Time (8:00 AM Eastern Time)</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the primary results from ACACIA-HCM (<strong>A</strong>ssessment <strong>C</strong>omparing <strong><em>A</em></strong><em>ficamten</em> to Placebo on <strong>C</strong>ardiac Endpoints <strong>I</strong>n <strong>A</strong>dults with Non-Obstructive <strong>HCM</strong>), the pivotal Phase http://www.streetinsider.com/Globe+Newswire/Cytokinetics+Announces+Positive+Results+from+ACACIA-HCM+Presented+in+Hot+Line+Session+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026+and+Published+in+The+New+England+Journal+of+Medicine/26992211.html Fri, 28 Aug 2026 05:45:00 -0400 A.06822034 A.09649487 A.33151435 CYTK O.00016952 O.00048429 O.02147044 O.20026344 http://www.streetinsider.com/Globe+Newswire/Cytokinetics+Announces+Positive+Results+from+ACACIA-HCM+Presented+in+Hot+Line+Session+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026+and+Published+in+The+New+England+Journal+of+Medicine/26992211.html <p align="center"><em>ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCM</em></p> <p align="center"><em>Supplemental New Drug Application to be Submitted to FDA in Fourth Quarter</em></p> <p align="center"><em>Company to Host Investor Event and Webcast Today at 2:00 PM Central European Summer Time (8:00 AM Eastern Time)</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the primary results from ACACIA-HCM (<strong>A</strong>ssessment <strong>C</strong>omparing <strong><em>A</em></strong><em>ficamten</em> to Placebo on <strong>C</strong>ardiac Endpoints <strong>I</strong>n <strong>A</strong>dults with Non-Obstructive <strong>HCM</strong>), the pivotal Phase http://www.streetinsider.com/Globe+Newswire/Cytokinetics+Announces+Positive+Results+from+ACACIA-HCM+Presented+in+Hot+Line+Session+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026+and+Published+in+The+New+England+Journal+of+Medicine/26992211.html Fri, 28 Aug 2026 05:45:00 -0400 A.06822034 A.09649487 A.33151435 CYTK O.00016952 O.00048429 O.02147044 O.20026344 http://www.streetinsider.com/Globe+Newswire/Cytokinetics+Announces+Positive+Results+from+ACACIA-HCM+Presented+in+Hot+Line+Session+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026+and+Published+in+The+New+England+Journal+of+Medicine/26992211.html <p align="center"><em>ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCM</em></p> <p align="center"><em>Supplemental New Drug Application to be Submitted to FDA in Fourth Quarter</em></p> <p align="center"><em>Company to Host Investor Event and Webcast Today at 2:00 PM Central European Summer Time (8:00 AM Eastern Time)</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the primary results from ACACIA-HCM (<strong>A</strong>ssessment <strong>C</strong>omparing <strong><em>A</em></strong><em>ficamten</em> to Placebo on <strong>C</strong>ardiac Endpoints <strong>I</strong>n <strong>A</strong>dults with Non-Obstructive <strong>HCM</strong>), the pivotal Phase http://www.streetinsider.com/Globe+Newswire/Cytokinetics+Announces+Positive+Results+from+ACACIA-HCM+Presented+in+Hot+Line+Session+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026+and+Published+in+The+New+England+Journal+of+Medicine/26992211.html Fri, 28 Aug 2026 05:45:00 -0400 A.06822034 A.09649487 A.33151435 CYTK O.00016952 O.00048429 O.02147044 O.20026344 http://www.streetinsider.com/Globe+Newswire/Cytokinetics+Announces+Positive+Results+from+ACACIA-HCM+Presented+in+Hot+Line+Session+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026+and+Published+in+The+New+England+Journal+of+Medicine/26992211.html <p align="center"><em>ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCM</em></p> <p align="center"><em>Supplemental New Drug Application to be Submitted to FDA in Fourth Quarter</em></p> <p align="center"><em>Company to Host Investor Event and Webcast Today at 2:00 PM Central European Summer Time (8:00 AM Eastern Time)</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the primary results from ACACIA-HCM (<strong>A</strong>ssessment <strong>C</strong>omparing <strong><em>A</em></strong><em>ficamten</em> to Placebo on <strong>C</strong>ardiac Endpoints <strong>I</strong>n <strong>A</strong>dults with Non-Obstructive <strong>HCM</strong>), the pivotal Phase http://www.streetinsider.com/Globe+Newswire/Cytokinetics+Announces+Positive+Results+from+ACACIA-HCM+Presented+in+Hot+Line+Session+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026+and+Published+in+The+New+England+Journal+of+Medicine/26992211.html Fri, 28 Aug 2026 05:45:00 -0400 A.06822034 A.09649487 A.33151435 CYTK O.00016952 O.00048429 O.02147044 O.20026344 http://www.streetinsider.com/Globe+Newswire/Cytokinetics+Announces+Positive+Results+from+ACACIA-HCM+Presented+in+Hot+Line+Session+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026+and+Published+in+The+New+England+Journal+of+Medicine/26992211.html <p align="center"><em>ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCM</em></p> <p align="center"><em>Supplemental New Drug Application to be Submitted to FDA in Fourth Quarter</em></p> <p align="center"><em>Company to Host Investor Event and Webcast Today at 2:00 PM Central European Summer Time (8:00 AM Eastern Time)</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the primary results from ACACIA-HCM (<strong>A</strong>ssessment <strong>C</strong>omparing <strong><em>A</em></strong><em>ficamten</em> to Placebo on <strong>C</strong>ardiac Endpoints <strong>I</strong>n <strong>A</strong>dults with Non-Obstructive <strong>HCM</strong>), the pivotal Phase http://www.streetinsider.com/Globe+Newswire/Cytokinetics+Announces+Positive+Results+from+ACACIA-HCM+Presented+in+Hot+Line+Session+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026+and+Published+in+The+New+England+Journal+of+Medicine/26992211.html Fri, 28 Aug 2026 05:45:00 -0400 A.06822034 A.09649487 A.33151435 CYTK O.00016952 O.00048429 O.02147044 O.20026344 http://www.streetinsider.com/Press+Releases/Cytokinetics+Announces+Upcoming+Presentations+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026/26952871.html <p align="center"><em>Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy</em></p> <p align="center"><em>Company to Host In-Person and Virtual Investor Event to Discuss Results from</em><br/><em>Late-Breaking Science Presentations </em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced upcoming presentations, including a Hot Line presentation and two Late Breaking Science presentations, at the European Society of Cardiology (ESC) Congress, taking place August 28-31 in Munich, Germany.</p> <p><strong>Hot Line and Late-Breaking Science Presentations</strong></p> <p><strong>Title: </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=dt13GbzCjdzO9XsP3HLGB5vA73vmYxkPJ0tySyv9Uj32SGqTFBQETC30jQmbXbouiVTVXVQyHDELo98z4I5IfuqiSzU1IPCYl7NQV4O6QueJAo4Knfw3S9J_Qw7Ztl-xre9a-givWDOQvaXktjv1r_FQxC95jSG3SxH5bgjfFGdLzKnd0MshLkksJRlfuwOVD9mw-QwlV9s8yEmyG3ipFyDJf7IUvcapB7E6kAEqz8A=" rel="nofollow" target="_blank">ACACIA-HCM: http://www.streetinsider.com/Press+Releases/Cytokinetics+Announces+Upcoming+Presentations+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026/26952871.html Thu, 20 Aug 2026 07:30:00 -0400 A.10255573 A.11887746 A.27952506 CYTK O.00016952 O.07416852 O.20227671 O.56853832 http://www.streetinsider.com/Press+Releases/Cytokinetics+Announces+Upcoming+Presentations+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026/26952871.html <p align="center"><em>Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy</em></p> <p align="center"><em>Company to Host In-Person and Virtual Investor Event to Discuss Results from</em><br/><em>Late-Breaking Science Presentations </em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced upcoming presentations, including a Hot Line presentation and two Late Breaking Science presentations, at the European Society of Cardiology (ESC) Congress, taking place August 28-31 in Munich, Germany.</p> <p><strong>Hot Line and Late-Breaking Science Presentations</strong></p> <p><strong>Title: </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=dt13GbzCjdzO9XsP3HLGB5vA73vmYxkPJ0tySyv9Uj32SGqTFBQETC30jQmbXbouiVTVXVQyHDELo98z4I5IfuqiSzU1IPCYl7NQV4O6QueJAo4Knfw3S9J_Qw7Ztl-xre9a-givWDOQvaXktjv1r_FQxC95jSG3SxH5bgjfFGdLzKnd0MshLkksJRlfuwOVD9mw-QwlV9s8yEmyG3ipFyDJf7IUvcapB7E6kAEqz8A=" rel="nofollow" target="_blank">ACACIA-HCM: http://www.streetinsider.com/Press+Releases/Cytokinetics+Announces+Upcoming+Presentations+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026/26952871.html Thu, 20 Aug 2026 07:30:00 -0400 A.10255573 A.11887746 A.27952506 CYTK O.00016952 O.07416852 O.20227671 O.56853832 http://www.streetinsider.com/Press+Releases/Cytokinetics+Announces+Upcoming+Presentations+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026/26952871.html <p align="center"><em>Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy</em></p> <p align="center"><em>Company to Host In-Person and Virtual Investor Event to Discuss Results from</em><br/><em>Late-Breaking Science Presentations </em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced upcoming presentations, including a Hot Line presentation and two Late Breaking Science presentations, at the European Society of Cardiology (ESC) Congress, taking place August 28-31 in Munich, Germany.</p> <p><strong>Hot Line and Late-Breaking Science Presentations</strong></p> <p><strong>Title: </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=dt13GbzCjdzO9XsP3HLGB5vA73vmYxkPJ0tySyv9Uj32SGqTFBQETC30jQmbXbouiVTVXVQyHDELo98z4I5IfuqiSzU1IPCYl7NQV4O6QueJAo4Knfw3S9J_Qw7Ztl-xre9a-givWDOQvaXktjv1r_FQxC95jSG3SxH5bgjfFGdLzKnd0MshLkksJRlfuwOVD9mw-QwlV9s8yEmyG3ipFyDJf7IUvcapB7E6kAEqz8A=" rel="nofollow" target="_blank">ACACIA-HCM: http://www.streetinsider.com/Press+Releases/Cytokinetics+Announces+Upcoming+Presentations+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026/26952871.html Thu, 20 Aug 2026 07:30:00 -0400 A.10255573 A.11887746 A.27952506 CYTK O.00016952 O.07416852 O.20227671 O.56853832 http://www.streetinsider.com/Press+Releases/Cytokinetics+Announces+Upcoming+Presentations+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026/26952871.html <p align="center"><em>Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy</em></p> <p align="center"><em>Company to Host In-Person and Virtual Investor Event to Discuss Results from</em><br/><em>Late-Breaking Science Presentations </em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced upcoming presentations, including a Hot Line presentation and two Late Breaking Science presentations, at the European Society of Cardiology (ESC) Congress, taking place August 28-31 in Munich, Germany.</p> <p><strong>Hot Line and Late-Breaking Science Presentations</strong></p> <p><strong>Title: </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=dt13GbzCjdzO9XsP3HLGB5vA73vmYxkPJ0tySyv9Uj32SGqTFBQETC30jQmbXbouiVTVXVQyHDELo98z4I5IfuqiSzU1IPCYl7NQV4O6QueJAo4Knfw3S9J_Qw7Ztl-xre9a-givWDOQvaXktjv1r_FQxC95jSG3SxH5bgjfFGdLzKnd0MshLkksJRlfuwOVD9mw-QwlV9s8yEmyG3ipFyDJf7IUvcapB7E6kAEqz8A=" rel="nofollow" target="_blank">ACACIA-HCM: http://www.streetinsider.com/Press+Releases/Cytokinetics+Announces+Upcoming+Presentations+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026/26952871.html Thu, 20 Aug 2026 07:30:00 -0400 A.10255573 A.11887746 A.27952506 CYTK O.00016952 O.07416852 O.20227671 O.56853832 http://www.streetinsider.com/Press+Releases/Cytokinetics+Announces+Upcoming+Presentations+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026/26952871.html <p align="center"><em>Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy</em></p> <p align="center"><em>Company to Host In-Person and Virtual Investor Event to Discuss Results from</em><br/><em>Late-Breaking Science Presentations </em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced upcoming presentations, including a Hot Line presentation and two Late Breaking Science presentations, at the European Society of Cardiology (ESC) Congress, taking place August 28-31 in Munich, Germany.</p> <p><strong>Hot Line and Late-Breaking Science Presentations</strong></p> <p><strong>Title: </strong><a target="_blank" href="https://www.globenewswire.com/Tracker?data=dt13GbzCjdzO9XsP3HLGB5vA73vmYxkPJ0tySyv9Uj32SGqTFBQETC30jQmbXbouiVTVXVQyHDELo98z4I5IfuqiSzU1IPCYl7NQV4O6QueJAo4Knfw3S9J_Qw7Ztl-xre9a-givWDOQvaXktjv1r_FQxC95jSG3SxH5bgjfFGdLzKnd0MshLkksJRlfuwOVD9mw-QwlV9s8yEmyG3ipFyDJf7IUvcapB7E6kAEqz8A=" rel="nofollow" target="_blank">ACACIA-HCM: http://www.streetinsider.com/Press+Releases/Cytokinetics+Announces+Upcoming+Presentations+at+the+European+Society+of+Cardiology+%28ESC%29+Congress+2026/26952871.html Thu, 20 Aug 2026 07:30:00 -0400 A.10255573 A.11887746 A.27952506 CYTK O.00016952 O.07416852 O.20227671 O.56853832